Tysabri safety analysis
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Biogen Idec/Elan's safety analysis of its Crohn's disease and rheumatoid arthritis trials with Tysabri (natalizumab) found no new confirmed cases of progressive multifocal leukoencephalopathy, the firms state Oct. 17. The announcement follows the sponsors' earlier statement that a safety evaluation of their pivotal trials in multiple sclerosis found no new cases of PML. Biogen and Elan resubmitted Tysabri for marketing in September; a priority review has been requested (1Pharmaceutical Approvals Monthly October 2005, In Brief)...
You may also be interested in...
Tysabri resubmission
Biogen Idec and Elan are requesting a priority review for their resubmission of multiple sclerosis therapyTysabri (natalizumab). The sBLA submission, announced Sept. 26, includes a risk management plan with a patient registry, revised labeling, final two-year data from the Phase III AFFIRM monotherapy trial and SENTINEL add-on study with Avonex (interferon beta-1a), as well as an integrated safety assessment of all patients treated with the biologic in clinical trials. The safety data set includes not only the MS pivotal trials but also Crohn's disease and rheumatoid arthritis trials (1Pharmaceutical Approvals Monthly August 2005, In Brief). Biogen Idec previously stated it expects an advisory committee review of the resubmission. Tysabri was withdrawn from the market in February following reports of progressive multifocal leukoencephalopathy from clinical trials...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.